~~<i id='9E32392CBB'><strike id='9E32392CBB'><tt id='9E32392CBB'><pre id='9E32392CBB'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

leisure time

author：fashion 2025-08-20 09:41:38 - browse：5

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： The cancer stories no one wants to hear

hotspot

knowledge

focus

hotspot

focus

MITeconomistAmyFinkelsteinchatswithSTAT'sBobHermanatthe2023STATSummit.STATFixingtheU.S.healthcaresys

WSS

Health tech investors get more selective as pandemic boom fades

Why a market frenzy over new weight loss drugs defies logic

J&J lung cancer data amount to new salvo against AstraZeneca

Health tech investors get more selective as pandemic boom fades

Roche drug slashes death risk in early

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

focus

leisure time

hotspot

Tori Bowie and the unacceptable rates of Black maternal death

Health tech investors get more selective as pandemic boom fades

How one medical school became remarkably diverse

STAT Summit: How researchers deal with rejection

Tori Bowie and the unacceptable rates of Black maternal death

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Peter Hotez and the public health issue of online harassment

2 officers injured in shooting in Orlando, police say

How to save PrEP access — and even expand it

'Null' research findings aren't empty of meaning. Let's publish them

knowledge

2 officers injured in shooting in Orlando, police say

2 officers injured in shooting in Orlando, police say

Results on Novartis prostate cancer therapy could expand its use

Cassava Sciences’ Alzheimer’s clinical trials should be halted

The problems with dementia villages

H.R. 3 is the wrong path to lower drug costs

focus

hotspot

focus

focus